Bright Minds Biosciences

Firefly Neuroscience, Inc. (NASDAQ:AIFF) announced a collaboration with Bright Minds Biosciences Inc. (NASDAQ:DRUG) to analyze data from the first-in-human Phase 1 study of BMB-101, Bright Minds’ lead compound for neuropsychiatric disorders and refractory epilepsy. Firefly employed its...

Bright Minds Biosciences Inc. (NASDAQ:DRUG) has released its Management’s Discussion and Analysis (MD&A) for the third quarter ending June 30, 2024, showcasing a substantial reduction in net losses as the company advances its research and development (R&D) initiatives. Q3 2024...

Wall Street is welcoming yet another company working with psychedelic molecules for mental health and neurological treatments. Bright Minds Biosciences (CSE: DRUG) received approval on Wednesday to effectively list its stock on the Nasdaq starting next Monday, November 8 under the symbol “...

National Cannabis Roundtable Welcomes Former Obama Official Kathleen Sebelius National Cannabis Roundtable (NCR) has welcomed yet another politician in its ranks. Kathleen Sebelius, the U.S. Department of Health and Human Services secretary under former President Barack Obama, has joined the group...